PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Atea Pharmaceuticals, Inc. (AVIR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS04683R1068
CUSIP04683R106
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$313.09M
EPS-$1.63
Revenue (TTM)$192.18M
Gross Profit (TTM)-$81.94M
EBITDA (TTM)-$119.59M
Year Range$2.77 - $5.19
Target Price$3.50
Short %2.57%
Short Ratio3.77

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Atea Pharmaceuticals, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Atea Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%NovemberDecember2024FebruaryMarchApril
-87.80%
55.10%
AVIR (Atea Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Atea Pharmaceuticals, Inc. had a return of 21.31% year-to-date (YTD) and 12.46% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date21.31%6.33%
1 month-3.14%-2.81%
6 months25.00%21.13%
1 year12.46%24.56%
5 years (annualized)N/A11.55%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202436.39%3.61%-6.26%
2023-10.71%8.33%-8.00%2.01%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AVIR is 58, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of AVIR is 5858
Atea Pharmaceuticals, Inc.(AVIR)
The Sharpe Ratio Rank of AVIR is 5959Sharpe Ratio Rank
The Sortino Ratio Rank of AVIR is 6161Sortino Ratio Rank
The Omega Ratio Rank of AVIR is 5959Omega Ratio Rank
The Calmar Ratio Rank of AVIR is 5757Calmar Ratio Rank
The Martin Ratio Rank of AVIR is 5656Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Atea Pharmaceuticals, Inc. (AVIR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AVIR
Sharpe ratio
The chart of Sharpe ratio for AVIR, currently valued at 0.25, compared to the broader market-2.00-1.000.001.002.003.000.25
Sortino ratio
The chart of Sortino ratio for AVIR, currently valued at 0.94, compared to the broader market-4.00-2.000.002.004.006.000.94
Omega ratio
The chart of Omega ratio for AVIR, currently valued at 1.11, compared to the broader market0.501.001.501.11
Calmar ratio
The chart of Calmar ratio for AVIR, currently valued at 0.16, compared to the broader market0.002.004.006.000.16
Martin ratio
The chart of Martin ratio for AVIR, currently valued at 0.51, compared to the broader market0.0010.0020.0030.000.51
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.002.004.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Atea Pharmaceuticals, Inc. Sharpe ratio is 0.25. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
0.25
1.91
AVIR (Atea Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Atea Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-95.82%
-3.48%
AVIR (Atea Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Atea Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Atea Pharmaceuticals, Inc. was 96.83%, occurring on Nov 22, 2023. The portfolio has not yet recovered.

The current Atea Pharmaceuticals, Inc. drawdown is 95.82%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.83%Feb 9, 2021703Nov 22, 2023
-22.86%Nov 9, 20201Nov 9, 202013Nov 27, 202014
-19.37%Nov 30, 20208Dec 9, 20208Dec 21, 202016
-7.22%Nov 2, 20202Nov 3, 20201Nov 4, 20203
-7.15%Feb 4, 20211Feb 4, 20212Feb 8, 20213

Volatility

Volatility Chart

The current Atea Pharmaceuticals, Inc. volatility is 8.79%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%NovemberDecember2024FebruaryMarchApril
8.79%
3.59%
AVIR (Atea Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Atea Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items